Why is coronary collateral growth impaired in type II diabetes and the metabolic syndrome?

Vascular Pharmacology

Volumn 57, Issue 5-6, 2012, Pages 179-186

  Rocic, Petra ^a  

^a UNIVERSITY OF SOUTH ALABAMA   (United States)

Author keywords

Collateral growth; Diabetes

Indexed keywords

ANGIOSTATIN; ANGIOTENSIN II; CYTOKINE; ENDOSTATIN; FIBROBLAST GROWTH FACTOR; GROWTH FACTOR; INTERCELLULAR ADHESION MOLECULE 1; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; THROMBOSPONDIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; BONE MARROW; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY COLLATERAL CIRCULATION; CYTOKINE PRODUCTION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; HEART MUSCLE REVASCULARIZATION; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNE SYSTEM; INFLAMMATION; LEUKOCYTE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE;

ANIMALS; COLLATERAL CIRCULATION; CORONARY CIRCULATION; CORONARY OCCLUSION; CYTOKINES; DIABETES MELLITUS, TYPE 2; EXTRACELLULAR MATRIX; HUMANS; METABOLIC SYNDROME X; SEVERITY OF ILLNESS INDEX;

EID: 84865658925     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2012.02.001     Document Type: Review

References (98)

1. Bergers G., Brekken R., McMahon G., Vu T.H., Itoh T., Tamaki K., et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2000 Oct, 2(10):737-744.
2. Boerth N.J., Dey N.B., Cornwell T.L., Lincoln T.M. Cyclic GMP-dependent protein kinase regulates vascular smooth muscle cell phenotype. J. Vasc. Res. 1997, 34:245-259.
3. Brackbill M.L., Sytsma C.S., Sykes K. Perioperative outcomes of coronary artery bypass grafting: effects of metabolic syndrome and patient's sex. Am. J. Crit. Care 2009, 18:468-473.
4. Cai W., Schaper W. Mechanisms of arteriogenesis. Acta Biochim. Biophys. Sin. 2008, 40:681-692.
5. Cai W.J., Kocsis E., Wu X., Rodríguez M., Luo X., Schaper W., et al. Remodeling of the vascular tunica media is essential for development of collateral vessels in the canine heart. Mol. Cell. Biochem. 2004, 264:201-210.
6. Cai W.J., Li M.B., Wu X., Wu S., Zhu W., Chen D., et al. Activation of the integrins alpha 5beta 1 and alpha v beta 3 and focal adhesion kinase (FAK) during arteriogenesis. Mol. Cell. Biochem. 2009, 322:161-169.
7. Carrão A.C., Chilian W.M., Yun J., Kolz C., Rocic P., Lehmann K., et al. Stimulation of coronary collateral growth by granulocyte stimulating factor: role of reactive oxygen species. Arterioscler. Thromb. Vasc. Biol. 2009, 29:1817-1822.
8. Chen J., Chen S., Chen Y., Zhang C., Wang J., Zhang W., et al. Circulating endothelial progenitor cells and cellular membrane microparticles in db/db diabetic mouse: possible implications in cerebral ischemic damage. Am. J. Physiol. Endocrinol. Metab. 2011, 301:E62-E71.
9. Death A.K., Fisher E.J., McGrath K.C., Yue D.K. High glucose alters matrix metalloproteinase expression in two key vascular cells: potential impact on atherosclerosis in diabetes. Atherosclerosis 2003, 168:263-269.
10. Deindl E. Arteriogenesis: a focus on signal transduction cascades and transcription factors. Thromb. Haemost. 2007, 98:940-943.
11. Deindl E., Hoefer I.E., Fernandez B., Barancik M., Heil M., Strniskova M., et al. Involvement of the fibroblast growth factor system in adaptive and chemokine-induced arteriogenesis. Circ. Res. 2003, 92:561-568.
12. Ding H., Triggle C.R. Endothelial cell dysfunction and the vascular complications associated with type 2 diabetes: assessing the health of the endothelium. Vasc. Health Risk Manage. 2005, 1:55-71.
13. Dodd T., Jadhav R., Wiggins L., Stewart J., Smith E., Russell J.C., et al. MMPs 2 and 9 are essential for coronary collateral growth and are prominently regulated by p38 MAPK. J. Mol. Cell. Cardiol. 2011, 51:1015-1025.
14. Eitenmüller I., Volger O., Kluge A., Troidl K., Barancik M., Cai W.J. The range of adaptation by collateral vessels after femoral artery occlusion. Circ. Res. 2006, (15):656-662.
15. Funahashi Y., Shawber C.J., Sharma A., Kanamaru E., Choi Y.K., Kitajewski J. Notch modulates VEGF action in endothelial cells by inducing Matrix Metalloprotease activity. Vasc. Cell 2011, 3:2-22.
16. Gao X., Belmadani S., Picchi A., Xu X., Potter B.J., Tewari-Singh N., et al. Tumor necrosis factor-alpha induces endothelial dysfunction in Lepr(db) mice. Circulation 2007, 115:245-254.
17. Gao X., Zhang H., Schmidt A.M., Zhang C. AGE/RAGE produces endothelial dysfunction in coronary arterioles in type 2 diabetic mice. Am. J. Physiol. Heart Circ. Physiol. 2008, 295:H491-H498.
18. Ghosh S., Maity P. VEGF antibody plus cisplatin reduces angiogenesis and tumor growth in a xenograft model of ovarian cancer. J. Environ. Pathol. Toxicol. Oncol. 2010, 29:17-30.
19. Grundmann S., Hoefer I., Ulusans S., van Royen N., Schirmer S.H., Ozaki C.K., et al. Anti-tumor necrosis factor-{alpha} therapies attenuate adaptive arteriogenesis in the rabbit. Am. J. Physiol. Heart Circ. Physiol. 2005, 289:H1497-H1505.
20. Guerci B., Böhme P., Kearney-Schwartz A., Zannad F., Drouin P. Endothelial dysfunction and type 2 diabetes. Part 2: altered endothelial function and the effects of treatments in type 2 diabetes mellitus. Diabetes Metab. 2001, 27:436-447.
21. Halliwell B. The antioxidant paradox. Lancet 2000, 355:1179-1180.
22. Hanzu F.A., Palomo M., Kalko S.G., Parrizas M., Garaulet M., Escolar G., et al. Translational evidence of endothelial damage in obese individuals: inflammatory and prothrombotic responses. J. Thromb. Haemost. 2011, 9:1236-1245.
23. Hattan N., Chilian W.M., Park F., Rocic P. Restoration of coronary collateral growth in the Zucker obese rat: impact of VEGF and ecSOD. Basic Res. Cardiol. 2007, 102:217-223.
24. Heller R., Polack T., Gräbner R., Till U. Nitric oxide inhibits proliferation of human endothelial cells via a mechanism independent of cGMP. Atherosclerosis 1999, 144:49-57.
25. Henry T.D., Annex B.H., McKendall G.R., Azrin M.A., Lopez J.J., Giordano F.J., et al. The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 2003, 107:1359-1365.
26. Hiraoka N., Allen E., Apel I.J., Gyetko M.R., Weiss S.J. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell 1998 Oct 30, 95(3):365-377.
27. Hochberg I., Hoffman A., Levy A.P. Regulation of VEGF in diabetic patients with critical limb ischemia. Ann. Vasc. Surg. 2001, 15:388-392.
28. Hoefer I.E., Grundmann S., van Royen N., Voskuil M., Schirmer S.H., Ulusans S., et al. Leukocyte subpopulations and arteriogenesis: specific role of monocytes, lymphocytes and granulocytes. Atherosclerosis 2005, 181:285-293.
29. Hoffmann R., Stellbrink E., Schröder J., Grawe A., Vogel G., Blindt R., et al. Impact of the metabolic syndrome on angiographic and clinical events after coronary intervention using bare-metal or sirolimus-eluting stents. Am. J. Cardiol. 2007, 100:1347-1352.
30. Howard E.W., Benton R., Ahern-Moore J., Tomasek J.J. Cellular contraction of collagen lattices is inhibited by nonenzymatic glycation. Exp. Cell Res. 1996, 228:132-137.
31. Jadhav R., Dodd T., Smith E., Bailey E., Delucia A.L., Russell J.C., et al. Angiotensin type I receptor blockade in conjunction with enhanced Akt activation restores coronary collateral growth in the metabolic syndrome. Am. J. Physiol. Heart Circ. Physiol. 2011, 300:H1938-H1949.
32. Jialal I., Fadini G.P., Pollock K., Devaraj S. Circulating levels of endothelial progenitor cell mobilizing factors in the metabolic syndrome. Am. J. Cardiol. 2010, 106:1606-1608.
33. Jialal I., Devaraj S., Singh U., Huet B.A. Decreased number and impaired functionality of endothelial progenitor cells in subjects with metabolic syndrome: implications for increased cardiovascular risk. Atherosclerosis 2010, 211:297-302.
34. Jones W.S., Annex B.H. Growth factors for therapeutic angiogenesis in peripheral arterial disease. Curr. Opin. Cardiol. 2007, 22:458-463.
35. Kajimoto K., Kasai T., Miyauchi K., Hirose H., Yanagisawa N., Yamamoto T., et al. Metabolic syndrome predicts 10-year mortality in non-diabetic patients following coronary artery bypass surgery. Circ. J. 2008, 72:1481-1486.
36. Kaneko H., Anzai T., Takahashi T., Kohno T., Shimoda M., Sasaki A., et al. Role of vascular endothelial growth factor-A in development of abdominal aortic aneurysm. Cardiovasc. Res. 2011, 91:358-367.
37. Keeley E.C., Moorman J.R., Liu L., Gimple L.W., Lipson L.C., Ragosta M., et al. Plasma chemokine levels are associated with the presence and extent of angiographic coronary collaterals in chronic ischemic heart disease. PLoS One 2011, 6:e21174.
38. Kikuchi R., Takeshita K., Uchida Y., Kondo M., Cheng X.W., Nakayama T., et al. Pitavastatin-induced angiogenesis and arteriogenesis is mediated by Notch1 in a murine hindlimb ischemia model without induction of VEGF. Lab Invest. 2011, 91:691-703.
39. Kim J.Y., Mun H.S., Lee B.K., Yoon S.B., Choi E.Y., Min P.K., et al. Impact of metabolic syndrome and its individual components on the presence and severity of angiographic coronary artery disease. Yonsei Med. J. 2010, 51:676-682.
40. Kocaman S.A., Sahinarslan A., Akyel A., Timurkaynak T., Boyaci B., Cengel A. The association of circulating monocyte count with coronary collateral growth in patients with diabetes mellitus. Acta Diabetol. 2010, 47:49-54.
41. Lakka H.M., Laaksonen D.E., Lakka T.A., Niskanen L.K., Kumpusalo E., Tuomilehto J., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002, 288:2709-2716.
42. Lassaletta A.D., Chu L.M., Robich M.P., Elmadhun N.Y., Feng J., Burgess T.A., et al. Overfed Ossabaw swine with early stage metabolic syndrome have normal coronary collateral development in response to chronic ischemia. Basic Res. Cardiol. 2012, 107:1-11.
43. Lassègue B., Griendling K.K. NADPH oxidases: functions and pathologies in the vasculature. Arterioscler. Thromb. Vasc. Biol. 2010, 30:653-661.
44. Lee S., Jilani S.M., Nikolova G.V., Carpizo D., Iruela-Arispe M.L. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J. Cell Biol. 2005, 169:681-691.
45. Luo Y., Xu Z., Wan T., He Y., Jones D., Zhang H., et al. Endothelial-specific transgenesis of TNFR2 promotes adaptive arteriogenesis and angiogenesis. Arterioscler. Thromb. Vasc. Biol. 2010, 30:1307-1314.
46. Matsunaga T., Warltier D.C., Weihrauch D.W., Moniz M., Tessmer J., Chilian W.M. Ischemia-induced coronary collateral growth is dependent on vascular endothelial growth factor and nitric oxide. Circulation 2000, 102:3098-3103.
47. Matsunaga T., Warltier D.C., Tessmer J., Weihrauch D., Simons M., Chilian W.M. Expression of VEGF and angiopoietins-1 and -2 during ischemia-induced coronary angiogenesis. Am. J. Physiol. Heart Circ. Physiol. 2003, 285:H352-H358.
48. Meisner J.K., Price R.J. Spatial and temporal coordination of bone marrow-derived cell activity during arteriogenesis: regulation of the endogenous response and therapeutic implications. Microcirculation 2010, 17:583-599.
49. Miller S.J., Coppinger B.J., Zhou X., Unthank J.L. Antioxidants reverse age-related collateral growth impairment. J. Vasc. Res. 2010, 47:108-114.
50. Mohri M., Tomoike H., Noma M., Inoue T., Hisano K., Nakamura M. Duration of ischemia is vital for collateral development: repeated brief coronary artery occlusions in conscious dogs. Circ. Res. 1989, 64:287-296.
51. Mouquet F., Cuilleret F., Susen S., Sautière K., Marboeuf P., Ennezat P.V., et al. Metabolic syndrome and collateral vessel formation in patients with documented occluded coronary arteries: association with hyperglycaemia, insulin-resistance, adiponectin and plasminogen activator inhibitor-1. Eur. Heart J. 2009, 30:840-849.
52. Mukhopadhyay C.K., Chatterjee I.B. Free metal ion-independent oxidative damage of collagen. Protection by ascorbic acid. J. Biol. Chem. 1994, 269:30200-30205.
53. Olieslagers S., Pardali E., Tchaikovski V., ten Dijke P., Waltenberger J. TGF-b1/ALK5-induced monocyte migration involves PI3K and p38 pathways and is not negatively affected by diabetes mellitus. Cardiovasc. Res. 2011, 91:510-518.
54. Panutsopulos D., Zafiropoulos A., Krambovitis E., Kochiadakis G.E., Igoumenidis N.E., Spandidos D.A. Peripheral monocytes from diabetic patients with coronary artery disease display increased bFGF and VEGF mRNA expression. J. Transl. Med. 2003, 1:6.
55. Pöling J., Szibor M., Schimanski S., Ingelmann M.E., Rees W., Gajawada P., et al. Induction of smooth muscle cell migration during arteriogenesis is mediated by Rap2. Arterioscler. Thromb. Vasc. Biol. 2011, 31:2297-2305.
56. Pung Y.F., Chilian W.M. Corruption of coronary collateral growth in metabolic syndrome: role of oxidative stress. World J. Cardiol. 2010, 26:421-427.
57. Pung Y.F., Rocic P., Murphy M.P., Smith R.A., Hafemeister J., Ohanyan V. Resolution of mitochondrial oxidative stress rescues coronary collateral growth in Zucker obese fatty rats. Arterioscler. Thromb. Vasc. Biol. 2011, Dec 8. [Epub ahead of print].
58. Reddy G.K. AGE-related cross-linking of collagen is associated with aortic wall matrix stiffness in the pathogenesis of drug-induced diabetes in rats. Microvasc. Res. 2004, 68:132-142.
59. Reed R., Kolz C., Potter B., Rocic P. The mechanistic basis for the disparate effects of angiotensin II on coronary collateral growth. Arterioscler. Thromb. Vasc. Biol. 2008, 28:61-67.
60. Reed R., Potter B., Smith E., Jadhav R., Villalta P., Jo H., et al. Redox-sensitive Akt and Src regulate coronary collateral growth in metabolic syndrome. Am. J. Physiol. Heart Circ. Physiol. 2009, 296:H1811-H1821.
61. Reed R.P.B., Smith E., Jadhav R., Villalta P., Jo H., Rocic P. Redox-sensitive Akt and Src regulate coronary collateral growth in metabolic syndrome. Am. J. Physiol. Heart Circ. Physiol. 2009, 296:H1811-H1821.
62. Ren B., Deng Y., Mukhopadhyay A., Lanahan A.A., Zhuang Z.W., Moodie K.L. ERK1/2-Akt1 crosstalk regulates arteriogenesis in mice and zebrafish. J. Clin. Invest. 2010, 1217-1228.
63. Rissanen T.T., Markkanen J.E., Arve K., Rutanen J., Kettunen M.I., Vajanto I., et al. Fibroblast growth factor 4 induces vascular permeability, angiogenesis and arteriogenesis in a rabbit hindlimb ischemia model. FASEB J. 2003, 17:100-102.
64. Rocic P., Kolz C., Reed R., Potter B., Chilian W.M. Optimal reactive oxygen species concentration and p38 MAP kinase are required for coronary collateral growth. Am. J. Physiol. Heart Circ. Physiol. 2007, 292:H2729-H2736.
65. Roger V.L., Go A.S., Lloyd-Jones D.M., Adams R.J., Berry J.D., Brown T.M., et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 2011, 123:e18-e209.
66. Ruiter M.S., van Golde J.M., Schaper N.C., Stehouwer C.D., Huijberts M.S. Diabetes impairs arteriogenesis in the peripheral circulation: review of molecular mechanisms. Clin. Sci. (Lond) 2010, 119:225-238.
67. Russell J.C., Graham S.E., Richardson M. Cardiovascular disease in the JCR:LA-cp rat. Mol. Cell. Biochem. 1998, 188:113-126.
68. Sasmaz H., Yilmaz M.B. Coronary collaterals in obese patients: impact of metabolic syndrome. Angiology 2009, 60:164-168.
69. Schaper W. Collateral circulation: past and present. Basic Res. Cardiol. 2009, 104:5-21.
70. Schernthaner G. Cardiovascular mortality and morbidity in type-2 diabetes mellitus. Diabetes Res. Clin. Pract. 1996, Suppl, S3-13.
71. Schirmer S.H., Buschmann I.R., Jost M.M., Hoefer I.E., Grundmann S., Andert J.P., et al. Differential effects of MCP-1 and leptin on collateral flow and arteriogenesis. Cardiovasc. Res. 2004, 64:356-364.
72. Schirmer S.H., van Nooijen F.C., Piek J.J., van Royen N. Stimulation of collateral artery growth: travelling further down the road to clinical application. Heart 2009, 95:191-197.
73. Schirmer S.H., Bot P.T., Fledderus J.O., van der Laan A.M., Volger O.L., Laufs U., et al. Blocking interferon beta stimulates vascular smooth muscle cell proliferation and arteriogenesis. J. Biol. Chem. 2010, 285:34677-34685.
74. Scholtz D., Cai W., Schaper W. Arteriogenesis, a new concept of vascular adaptation in occlusive disease. Angiogenesis 2001, 4:247-257.
75. Sodha N.R., Clements R.T., Boodhwani M., Xu S.H., Laham R.J., Bianchi C., et al. Endostatin and angiostatin are increased in diabetic patients with coronary artery disease and associated with impaired coronary collateral formation. Am. J. Physiol. Heart Circ. Physiol. 2009, 296:H428-H434.
76. Steingen C., Brenig F., Baumgartner L., Schmidt J., Schmidt A., Bloch W. Characterization of key mechanisms in transmigration and invasion of mesenchymal stem cells. J. Mol. Cell. Cardiol. 2008 Jun, 44(6):1072-1084.
77. Sugiyama Y., Yagita Y., Oyama N., Terasaki Y., Omura-Matsuoka E., Sasaki T., et al. Granulocyte colony-stimulating factor enhances arteriogenesis and ameliorates cerebral damage in a mouse model of ischemic stroke. Stroke 2011, 42:770-775.
78. Suhr F., Brixius K., Bloch W. Angiogenic and vascular modulation by extracellular matrix cleavage products. Curr. Pharm. Des. 2009, 15(4):389-410.
79. Taniyama Y., Morishita R., Hiraoka K., Aoki M., Nakagami H., Yamasaki K., et al. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat diabetic hind limb ischemia model: molecular mechanisms of delayed angiogenesis in diabetes. Circulation 2001, 104:2344-2350.
80. Tongers J., Roncalli J.G., Losordo D.W. Role of endothelial progenitor cells during ischemia-induced vasculogenesis and collateral formation. Microvasc. Res. 2010, 79:200-206.
81. Toyota E., Warltier D.C., Brock T., Ritman E., Kolz C., O'Malley P., et al. Vascular endothelial growth factor is required for coronary collateral growth in the rat. Circulation 2005, 112:2108-2113.
82. Tritsaris K., Myren M., Ditlev S.B., Hübschmann M.V., van der Blom I., Hansen A.J., et al. IL-20 is an arteriogenic cytokine that remodels collateral networks and improves functions of ischemic hind limbs. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:15364-15369.
83. Troidl K., Tribulova S., Cai W.J., Eitenmüller I., Wustrack H., Schierling W. Effects of endogenous NO and of DETA NONOate in Arteriogenesis. J. Cardiovasc. Pharmacol. 2009, Epub ahead of print.
84. Troidl K., Rüding I., Cai W.J., Mücke Y., Grossekettler L., Piotrowska I., et al. Actin-binding rho activating protein (Abra) is essential for fluid shear stress-induced arteriogenesis. Arterioscler. Thromb. Vasc. Biol. 2009, 29:2093-2101.
85. Tsihlis N.D., Oustwani C.S., Vavra A.K., Jiang Q., Keefer L.K., Kibbe M.R. Nitric oxide inhibits vascular smooth muscle cell proliferation and neointimal hyperplasia by increasing the ubiquitination and degradation of UbcH10. Cell Biochem. Biophys. 2011, 60:89-97.
86. Urano T., Ito Y., Akao M., Sawa T., Miyata K., Tabata M., et al. Angiopoietin-related growth factor enhances blood flow via activation of the ERK1/2-eNOS-NO pathway in a mouse hind-limb ischemia model. Arterioscler. Thromb. Vasc. Biol. 2008, 28:827-834.
87. van Royen N., Hoefer I., Buschmann I., Heil M., Kostin S., Deindl E., et al. Exogenous application of transforming growth factor beta 1 stimulates arteriogenesis in the peripheral circulation. FASEB J. 2002, 16:432-434.
88. van Royen N., Schirmer S.H., Atasever B., Behrens C.Y., Ubbink D., Buschmann E.E., et al. START Trial: a pilot study on Stimulation of ARTeriogenesis using subcutaneous application of granulocyte-macrophage colony-stimulating factor as a new treatment for peripheral vascular disease. Circulation 2005, 112:1040-1046.
89. Waltenberger J., Lange J., Kranz A. Vascular endothelial growth factor-A-induced chemotaxis of monocytes is attenuated in patients with diabetes mellitus: a potential predictor for the individual capacity to develop collaterals. Circulation 2000, 11:185-190.
90. Wautier M.P., Chappey O., Corda S., Stern D.M., Schmidt A.M., Wautier J.L. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am. J. Physiol. Endocrinol. Metab. 2001, 280:E685-E694.
91. Weihrauch D., Lohr N.L., Mraovic B., Ludwig L.M., Chilian W.M., Pagel P.S., et al. Chronic hyperglycemia attenuates coronary collateral development and impairs proliferative properties of myocardial interstitial fluid by production of angiostatin. Circulation 2004, 109:2343-2348.
92. Yamanishi K., Fujita M., Ohno A., Sasayama S. Importance of myocardial ischaemia for recruitment of coronary collateral circulation in dogs. Cardiovasc. Res. 1990, 24:271-277.
93. Yang J., Park Y., Zhang H., Gao X., Wilson E., Zimmer W., et al. Role of MCP-1 in tumor necrosis factor-alpha-induced endothelial dysfunction in type 2 diabetic mice. Am. J. Physiol. Heart Circ. Physiol. 2009, 297:H1208-H1216.
94. Yilmaz M.B., Caldir V., Guray Y., Guray U., Altay H., Demirkan B. Relation of coronary collateral vessel development in patients with a totally occluded right coronary artery to the metabolic syndrome. Am. J. Cardiol. 2006, 636-639.
95. Yin L., Ohanyan V., Fen Pung Y., Delucia A., Bailey E., Enrick M., et al. Induction of vascular progenitor cells from endothelial cells stimulates coronary collateral growth. Circ. Res. 2011, [Epub ahead of print].
96. Yun J., Rocic P., Pung Y.F., Belmadani S., Carrao A.C., Ohanyan V., et al. Redox-dependent mechanisms in coronary collateral growth: the "redox window" hypothesis. Antioxid Redox Signal. 2009, 11:1961-1974.
97. Zachary I., Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc. Res. 2001, 49:568-581.
98. Zhou B., Bi Y.Y., Han Z.B., Ren H., Fang Z.H., Yu X.F., et al. G-CSF-mobilized peripheral blood mononuclear cells from diabetic patients augment neovascularization in ischemic limbs but with impaired capability. J. Thromb. Haemost. 2006, 4:993-1002.